- Home
- LX vs EVMN Comparison
LX vs EVMN Comparison
Compare LX & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
N/A
Current Price
$21.08
Company Overview
Basic Information| Metric | LX | EVMN |
|---|---|---|
| Founded | 2013 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.3M | 628.9M |
| IPO Year | 2017 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LX | EVMN |
|---|---|---|
| Price | $3.15 | $21.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.50 | ★ $38.60 |
| AVG Volume (30 Days) | ★ 1.8M | 329.7K |
| Earning Date | 11-24-2025 | 02-07-2026 |
| Dividend Yield | ★ 12.20% | N/A |
| EPS Growth | ★ 125.70 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $1,933,903,250.00 | $13,000,000.00 |
| Revenue This Year | N/A | $89.43 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.21 | ★ N/A |
| Revenue Growth | N/A | ★ 160.00 |
| 52 Week Low | $2.98 | $13.89 |
| 52 Week High | $11.64 | $24.03 |
Technical Indicators
Market Signals| Indicator | LX | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 40.76 | N/A |
| Support Level | $2.98 | N/A |
| Resistance Level | $3.44 | N/A |
| Average True Range (ATR) | 0.13 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 32.29 | 0.00 |
Price Performance
Historical Comparison LX
EVMN
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.